Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth Acquires Thiakis | Contract Pharma

What are you searching for?

Sign in
Breaking News

Wyeth Acquires Thiakis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth has acquired Thiakis Limited, a privately held biotechnology company based in the United Kingdom. Thiakis’ lead product candidate, TKS1225, is being studied for the treatment of medical obesity and other co-morbidities. TKS1225 and related compounds are synthetic versions of the natural gastrointestinal peptide oxyntomodulin.

Wyeth is paying approximately $30 million for Thiakis, with potential milestone payments of as much as $120 million. Thiakis was founded in 2004.

“This acquisition is evidence of our commitment to develop and bring to market innovative, high-value medicines that have the potential to address significant unmet needs in critical therapeutic areas such as metabolic disorders,” said Mikael Dolsten, M.D., Ph.D., president, Wyeth Research. “Thiakis’ R&D program fits well with our goal of addressing the medical burden of obesity in a targeted manner using biologic-based therapies.”

“As we take this important step with Wyeth, we are certain we have chosen the right company to follow through on our vision and commitment to develop and commercialize important new therapies that help address the growing worldwide medical epidemic of obesity,” says John Burt, D.Phil. ACMA, chief executive officer and co-founder of Thiakis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters